Tirzepatide Wholesale

39-amino acid dual GIP/GLP-1 receptor agonist — the differentiation leader in metabolic peptide portfolios

Product Identity

CAS Number2023788-19-2
Sequence39-amino acid with Aib²+Aib¹³ + C20 fatty diacid linker + C-terminal amidation
Molecular Weight~4,813.5 Da
AppearanceWhite to off-white lyophilized powder
Purity≥99% by HPLC
SolubilityPhosphate buffer (pH 7.4) or dilute acetic acid
Storage2–8°C, desiccated, protect from light

Configurations

ConfigurationContentBest For
Standard Kit5 mg × 10 vialsMost protocols; evaluation
Bulk Kit10 mg × 10 vialsHigh-throughput; OEM
CustomCustom mg × custom vialsPrivate-label; protocol-specific

Research Background

Tirzepatide is an "imbalanced" dual agonist — it activates both GIP and GLP-1 receptors but with ~5× greater GIPR potency. This dual mechanism is the basis for its enhanced metabolic efficacy over selective GLP-1 agonists.

Structural Features

GIP-backbone designBased on native GIP → greater GIPR potency (5× GIPR vs GLP-1R)
Aib², Aib¹³DPP-4 resistance → extended half-life
C20 fatty diacidLonger chain than Semaglutide's C18 → stronger albumin binding (~5-day t½)
C-terminal Pro-richPro-Pro-Pro-Ser-NH₂ → receptor selectivity optimization
AEEA-AEEA-γ-Glu spacerOptimal separation between peptide and albumin-binding moiety

Receptor Activity

ParameterGIP ReceptorGLP-1 Receptor
Binding Affinity (Ki)~2.3 nM~12.6 nM
Functional Activity (EC₅₀)~0.06 nM (cAMP)~0.03 nM (cAMP)
Relative Potency~5× more potentReference

Research Focus Areas

Body Weight

~22.5% mean reduction (SURMOUNT-1); >GLP-1 alone

Glycemic Control

HbA1c reduction up to 2.4%; superior to Semaglutide 1mg

Lipid Metabolism

Improved lipid profiles; reduced triglycerides

Insulin Sensitivity

Improved beyond weight loss alone (GIP-mediated)

NASH/NAFLD

Reduced liver fat content; under investigation for NASH

Tirzepatide vs Semaglutide vs Retatrutide

ParameterSemaglutideTirzepatideRetatrutide
ReceptorGLP-1RGIPR + GLP-1RGIPR + GLP-1R + GCGR
Amino Acids313939
MW~4,113.6 Da~4,813.5 Da~4,845.5 Da
LinkerC18C20C20
BW Reduction~15%~22.5%~24.2% (Ph2)
B2B PositionVolume leaderDifferentiationInnovation

Quality Specifications

ParameterMethodCriterion
PurityHPLC at 214 nm≥99.0% peak area
Identity (MW)ESI-MS~4,813.5 ± 1.5 Da
AppearanceVisualWhite to off-white powder
Peptide ContentAAA / elemental≥80% net peptide
Residual MoistureKarl Fischer≤3%
Linker IntegrityHPLC-ELSD / LC-MS/MSIntact C20 linker (bulk)

Tirzepatide purification is more challenging than Semaglutide — 39 AA with closely related deletion peptides and oxidation products require optimized HPLC gradients.

Tiered Wholesale Pricing

VolumeDiscountFor
1 kitList priceEvaluation; competitive analysis
2–5 kits10–20% offInitial portfolio expansion
6–20 kits25–40% offMid-size distributors
21–50 kits40–55% offRegional distributors
50+ kits55–70% offLarge distributors; recurring

FAQ

How does Tirzepatide differ from Semaglutide mechanistically?

Semaglutide activates only GLP-1R. Tirzepatide activates both GIPR and GLP-1R — the GIP component adds insulinotropic effects, improved lipid handling, and better insulin sensitivity. Read the full comparison in our GLP-1 Buyer's Guide →

Why is Tirzepatide more expensive than Semaglutide?

Three factors: longer sequence (39 vs 31 AA → more coupling steps, higher material costs), more challenging purification, and higher demand relative to capacity (Tirzepatide is in "differentiation" phase with growing demand).

What salt form is your Tirzepatide?

Standard is the acetate salt. If your protocol requires Na, TFA, or another counterion, specify in your inquiry — salt form can be adjusted during the final purification/lyophilization stage.

How do you confirm the identity — not just purity — of Tirzepatide?

Every batch undergoes both HPLC (purity, ≥99% peak area) AND ESI-MS (identity, confirming MW ~4,813.5 Da). For bulk orders: linker integrity by HPLC-ELSD or LC-MS/MS to confirm intact C20 fatty diacid conjugation.

FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary diagnostic, therapeutic, or any clinical use.

Ready to Source Tirzepatide?

Premium dual-agonist differentiation. Tiered pricing up to 70%. COA + MS + linker integrity with every bulk order.

← Back to Metabolic